JP2018534263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534263A5 JP2018534263A5 JP2018516487A JP2018516487A JP2018534263A5 JP 2018534263 A5 JP2018534263 A5 JP 2018534263A5 JP 2018516487 A JP2018516487 A JP 2018516487A JP 2018516487 A JP2018516487 A JP 2018516487A JP 2018534263 A5 JP2018534263 A5 JP 2018534263A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- group
- composition
- inhibitor
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003112 inhibitor Substances 0.000 claims description 69
- 229940124291 BTK inhibitor Drugs 0.000 claims description 26
- -1 4-phenoxyphenyl Chemical group 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 229940122245 Janus kinase inhibitor Drugs 0.000 claims description 15
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 229960004641 rituximab Drugs 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 229960004397 cyclophosphamide Drugs 0.000 claims description 12
- 229960000390 fludarabine Drugs 0.000 claims description 12
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 10
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 9
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 claims description 8
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 8
- 229960004618 prednisone Drugs 0.000 claims description 8
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 8
- 230000000172 allergic effect Effects 0.000 claims description 7
- 208000010668 atopic eczema Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 229960002707 bendamustine Drugs 0.000 claims description 6
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims description 6
- 229960004630 chlorambucil Drugs 0.000 claims description 6
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 229960004528 vincristine Drugs 0.000 claims description 6
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 6
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 229940127254 ASK1 inhibitor Drugs 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 4
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 102000054439 human MMP9 Human genes 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- ASUGUQWIHMTFJL-QGZVFWFLSA-N (2r)-2-methyl-2-[[2-(1h-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]-n-(2,2,2-trifluoroethyl)butanamide Chemical compound FC(F)(F)CNC(=O)[C@@](C)(CC)NC1=CC=NC(C=2C3=CC=CN=C3NC=2)=N1 ASUGUQWIHMTFJL-QGZVFWFLSA-N 0.000 claims description 3
- ISOCDPQFIXDIMS-QHCPKHFHSA-N (2s)-n-[4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]phenyl]pyrrolidine-2-carboxamide Chemical compound O=C([C@H]1NCCC1)NC(C=C1)=CC=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 ISOCDPQFIXDIMS-QHCPKHFHSA-N 0.000 claims description 3
- DCRWIATZWHLIPN-UHFFFAOYSA-N (4-fluorophenyl)-[4-[(5-methyl-1h-pyrazol-3-yl)amino]quinazolin-2-yl]methanol Chemical compound N1C(C)=CC(NC=2C3=CC=CC=C3N=C(N=2)C(O)C=2C=CC(F)=CC=2)=N1 DCRWIATZWHLIPN-UHFFFAOYSA-N 0.000 claims description 3
- IBPVXAOOVUAOKJ-UHFFFAOYSA-N 4-[[2,6-difluoro-4-[3-(1-piperidin-4-ylpyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine Chemical compound FC1=CC(C=2C3=NC(=CN=C3C=CC=2)C2=CN(N=C2)C2CCNCC2)=CC(F)=C1CN1CCOCC1 IBPVXAOOVUAOKJ-UHFFFAOYSA-N 0.000 claims description 3
- DVCPYUTZIIXGFE-UHFFFAOYSA-N 649nj54i9p Chemical compound ClC1=CC=CC(Cl)=C1C1=NC(C2=CC=CN=C2NC2=CN=CC=C22)=C2N1 DVCPYUTZIIXGFE-UHFFFAOYSA-N 0.000 claims description 3
- 239000004012 Tofacitinib Substances 0.000 claims description 3
- 229950006663 filgotinib Drugs 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- RFZKSQIFOZZIAQ-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)phenyl]-8-(4-methylsulfonylphenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine Chemical compound C1CN(C)CCN1C1=CC=CC(NC2=NN3C=CC=C(C3=N2)C=2C=CC(=CC=2)S(C)(=O)=O)=C1 RFZKSQIFOZZIAQ-UHFFFAOYSA-N 0.000 claims description 3
- RIJLVEAXPNLDTC-UHFFFAOYSA-N n-[5-[4-[(1,1-dioxo-1,4-thiazinan-4-yl)methyl]phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NC(=NN12)N=C1C=CC=C2C(C=C1)=CC=C1CN1CCS(=O)(=O)CC1 RIJLVEAXPNLDTC-UHFFFAOYSA-N 0.000 claims description 3
- IGLNXKVGKIFNBQ-UHFFFAOYSA-N n-[5-[[5-fluoro-4-(4-prop-2-ynoxyanilino)pyrimidin-2-yl]amino]-2-methylphenyl]sulfonylpropanamide Chemical compound C1=C(C)C(S(=O)(=O)NC(=O)CC)=CC(NC=2N=C(NC=3C=CC(OCC#C)=CC=3)C(F)=CN=2)=C1 IGLNXKVGKIFNBQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001350 tofacitinib Drugs 0.000 claims description 3
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 2
- 108091005575 Bromodomain-containing proteins Proteins 0.000 claims description 2
- 102000001805 Bromodomains Human genes 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 2
- 241001061127 Thione Species 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 238000011319 anticancer therapy Methods 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004679 doxorubicin Drugs 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 2
- 239000003607 modifier Substances 0.000 claims description 2
- 229960003347 obinutuzumab Drugs 0.000 claims description 2
- 229960002450 ofatumumab Drugs 0.000 claims description 2
- 238000011275 oncology therapy Methods 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 150000003573 thiols Chemical class 0.000 claims description 2
- 229940066958 treanda Drugs 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 28
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 claims 10
- 241000282412 Homo Species 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 210000004180 plasmocyte Anatomy 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 18
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 18
- 238000000034 method Methods 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- KTBSXLIQKWEBRB-UHFFFAOYSA-N 2-[1-[1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl]-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C1=CN=C(C(F)(F)F)C(F)=C1C(=O)N1CCC(N2CC(CC#N)(C2)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CC1 KTBSXLIQKWEBRB-UHFFFAOYSA-N 0.000 description 1
- KQQLBXFPTDVFAJ-UHFFFAOYSA-N CHZ868 Chemical compound CC(=O)Nc1cc(Oc2ccc3n(C)c(Nc4ccc(F)cc4F)nc3c2C)ccn1 KQQLBXFPTDVFAJ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- NSGDYZCDUPSTQT-UHFFFAOYSA-N N-[5-bromo-1-[(4-fluorophenyl)methyl]-4-methyl-2-oxopyridin-3-yl]cycloheptanecarboxamide Chemical compound Cc1c(Br)cn(Cc2ccc(F)cc2)c(=O)c1NC(=O)C1CCCCCC1 NSGDYZCDUPSTQT-UHFFFAOYSA-N 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- JCINBYQJBYJGDM-UHFFFAOYSA-N bms-911543 Chemical compound CCN1C(C(=O)N(C2CC2)C2CC2)=CC(C=2N(C)C=NC=22)=C1N=C2NC=1C=C(C)N(C)N=1 JCINBYQJBYJGDM-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- MPYACSQFXVMWNO-UHFFFAOYSA-N n-[5-[4-(3,3-dimethylazetidine-1-carbonyl)phenyl]-[1,2,4]triazolo[1,5-a]pyridin-2-yl]cyclopropanecarboxamide Chemical compound C1C(C)(C)CN1C(=O)C1=CC=C(C=2N3N=C(NC(=O)C4CC4)N=C3C=CC=2)C=C1 MPYACSQFXVMWNO-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562236729P | 2015-10-02 | 2015-10-02 | |
| US201562236409P | 2015-10-02 | 2015-10-02 | |
| US201562236741P | 2015-10-02 | 2015-10-02 | |
| US201562236345P | 2015-10-02 | 2015-10-02 | |
| US62/236,741 | 2015-10-02 | ||
| US62/236,409 | 2015-10-02 | ||
| US62/236,345 | 2015-10-02 | ||
| US62/236,729 | 2015-10-02 | ||
| PCT/US2016/054780 WO2017059252A1 (en) | 2015-10-02 | 2016-09-30 | Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187956A Division JP2021014466A (ja) | 2015-10-02 | 2020-11-11 | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018534263A JP2018534263A (ja) | 2018-11-22 |
| JP2018534263A5 true JP2018534263A5 (cg-RX-API-DMAC7.html) | 2019-11-07 |
Family
ID=57184801
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018516487A Withdrawn JP2018534263A (ja) | 2015-10-02 | 2016-09-30 | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
| JP2020187956A Pending JP2021014466A (ja) | 2015-10-02 | 2020-11-11 | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020187956A Pending JP2021014466A (ja) | 2015-10-02 | 2020-11-11 | 癌、アレルギー性障害、自己免疫性疾患または炎症性疾患を治療するための、ｊａｋ阻害物質、ａｓｋ１阻害物質、ｂｒｄ阻害物質及び／またはｍｍｐ９阻害物質から選択される阻害物質とｂｔｋ阻害物質ｇｓ−４０５９の組み合わせ |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3355871A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2018534263A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016329075A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3000746A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1258762A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201726130A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017059252A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201806320D0 (en) | 2018-04-18 | 2018-05-30 | Cellcentric Ltd | Process |
| KR20210079313A (ko) * | 2018-10-19 | 2021-06-29 | 센화 바이오사이언시즈 인코포레이티드 | 암 치료에서 면역 조절을 위한 조합 |
| CN109912584B (zh) * | 2019-03-22 | 2021-08-13 | 中国药科大学 | 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用 |
| CN110403944A (zh) * | 2019-08-07 | 2019-11-05 | 中南大学湘雅医院 | Decernotinib在制备治疗银屑病的外用药物中的应用、药物及制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014012727B1 (pt) * | 2011-11-29 | 2022-10-25 | Ono Pharmaceutical Co., Ltd | Cloridrato de 6-amino-9-[(3r)-1-(2-butinoil)-3-pirrolidinil]-7-(4-fenoxifenil)-7,9-di-hidro-8h-puri- 8-ona e composição farmacêutica |
| UY34573A (es) * | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
| SG11201405273YA (en) * | 2012-02-29 | 2014-09-26 | Gilead Biologics Inc | Antibodies to matrix metalloproteinase 9 |
| BR112014032346A2 (pt) * | 2012-06-26 | 2017-06-27 | Del Mar Pharmaceuticals | métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes |
| MX369503B (es) * | 2013-04-08 | 2019-11-11 | Pharmacyclics Llc | Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas. |
| TWI527811B (zh) * | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| MY178726A (en) * | 2013-11-07 | 2020-10-20 | Hoffmann La Roche | Combination therapy of an afucosylated cd20 antibody with a btk inhibitor |
| CA2931615A1 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| ES2806506T3 (es) * | 2014-03-25 | 2021-02-17 | Ono Pharmaceutical Co | Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes |
| US9949971B2 (en) * | 2014-06-17 | 2018-04-24 | Acerta Pharma B.V. | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor |
-
2016
- 2016-09-30 AU AU2016329075A patent/AU2016329075A1/en not_active Abandoned
- 2016-09-30 JP JP2018516487A patent/JP2018534263A/ja not_active Withdrawn
- 2016-09-30 WO PCT/US2016/054780 patent/WO2017059252A1/en not_active Ceased
- 2016-09-30 EP EP16785022.1A patent/EP3355871A1/en not_active Withdrawn
- 2016-09-30 CA CA3000746A patent/CA3000746A1/en not_active Abandoned
- 2016-09-30 HK HK19101080.8A patent/HK1258762A1/zh unknown
- 2016-09-30 TW TW105131809A patent/TW201726130A/zh unknown
-
2020
- 2020-11-11 JP JP2020187956A patent/JP2021014466A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534263A5 (cg-RX-API-DMAC7.html) | ||
| TWI794171B (zh) | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 | |
| CN108289892B (zh) | 治疗组合物、组合和使用方法 | |
| JP2022017296A (ja) | Ｈｄａｃ阻害剤とｐｄ－１阻害剤との組み合わせ療法 | |
| JP7307744B2 (ja) | がん治療のための１－（ピペリジノカルボニルメチル）－２－オキソピペラジン誘導体 | |
| JP7592689B2 (ja) | Ｓｔｉｎｇアゴニストとしての大環状化合物並びにその方法及び使用 | |
| AU2017362040B2 (en) | Dose and regimen for HDM2-p53 interaction inhibitors | |
| CN108348521A (zh) | 用于治疗癌症的5-溴-2,6-二-(1h-吡唑-1-基)嘧啶-4-胺 | |
| JP2014533284A5 (cg-RX-API-DMAC7.html) | ||
| JP2024513505A (ja) | 腫瘍を治療するための組成物及び方法 | |
| JP2018517686A5 (cg-RX-API-DMAC7.html) | ||
| JP5948525B1 (ja) | 癌のための併用療法 | |
| AU2011278227A1 (en) | Superior efficacy of CD37 antibodies in CLL blood samples | |
| CN113811298B (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| JP2025061387A (ja) | 複素環式タンパク質キナーゼ阻害剤を含む製剤 | |
| US12227577B2 (en) | Combination of a PD-1 antagonist, an ATR inhibitor and a platinating agent for the treatment of cancer | |
| CN112384219A (zh) | Sumo-激活酶抑制剂和抗cd20抗体的施用 | |
| TWI812820B (zh) | 使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法 | |
| US20240398943A1 (en) | Methods of treating cancer and the pharmaceutical compositions thereof | |
| CN113766917A (zh) | 用于治疗头颈癌的喹啉衍生物 | |
| KR20230010659A (ko) | Sumo-활성화 효소 억제제 및 항-cd38 항체의 투여 | |
| US20220380476A1 (en) | Use of an anti-CCR7 antibody in combination therapies with a BTK inhibitor and/or BCL2- inhibitor for treating hematological malignancies | |
| HK40058495B (zh) | 抗肿瘤组合物 | |
| EA049231B1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛА ПРОТИВ CCR7 В КОМБИНИРОВАННОЙ ТЕРАПИИ С ИНГИБИТОРОМ BTK И/ИЛИ ИНГИБИТОРОМ Bcl-2 ПРИ ЛЕЧЕНИИ ГЕМАТОЛОГИЧЕСКИХ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ |